Consultants expect M&A tempo to continue

Share this article:
GSK, Novartis, Lilly play musical chairs
M&A activity has felt like a sprint for the first half of this year

M&A activity has felt like a sprint for the first half of this year. Consulting firm PwC anticipates that the year's second half will also see some notable deals, but the firm's first-half analysis shows that the numbers behind the recent noise can be a little misleading.

Among the consultancy's findings: while the number of second-quarter pharmaceutical industry deals (11) was about the same as the number of deals that closed during the second quarter of 2013, the value of the more recent deals fell 54.6%. Biotechnology M&A showed a similar result: the number of this year's second-quarter deals inched past those of 2013, but the value of these deals were 28% less.

PwC notes that divestitures—worth around $7.7 billion—fed this year's run of mergers and acquisitions and anticipates additional ones “are likely to continue to fuel the M&A activity in the upcoming quarters.”

Among PwC's list of this year's notable transactions so far: The Novartis-Lilly-GSK swap, Forest's Furiex Pharmaceuticals purchase, Bayer's Merck OTC sweep, and Merck's Idenix buy.

The firm notes that 20 deals that were announced during the first six months have yet to close and represent around 61.9% of the total value of deals announced during the second quarter of this year.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...